• Login
KindredBio
  • About
    • Background
    • KindredBio Leadership
    • Board of Directors
  • Technology
    • Veterinary Recombinant Biologics
    • Manufacturing Process
  • Products
    • Mirataz® (mirtazapine transdermal ointment)
      • Mirataz home
      • About Feline Weight Loss
      • Mechanism of Action
      • Efficacy
      • Safety
      • Dosing and Administration
      • Resources
      • Mirataz News
      • For Cat Owners
      • Frequently Asked Questions
  • Investors
    • Investor Overview
    • Press Releases
    • Events & Presentations
    • Pipeline
      • Pipeline
      • Zimeta™ (dipyrone)
      • epoCat™ (feline recombinant erythropoietin)
    • Corporate Governance
    • Stock Information
    • Financial Information
    • Investor Resources
  • News
    • Press Releases
  • Contact Us
    • Contact Us
    • Careers
  • Search
  • Menu

login

You are here: Home / login
Username
Password

» Lost your Password?

News

  • Kindred Biosciences Announces Fourth Quarter and Full Year 2018 Financial ResultsMarch 6, 2019 - 4:02 pm
  • Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial ResultsFebruary 19, 2019 - 8:44 am
  • Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare ConferenceFebruary 13, 2019 - 8:33 am

Events

  • Event: Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial ResultsFebruary 19, 2019 - 8:45 am
  • Event: Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health SummitFebruary 13, 2019 - 8:37 am
  • Event: Kindred Biosciences to Present at Barclays Global Healthcare ConferenceFebruary 13, 2019 - 8:35 am
$8.27 Stock is Down -0.58 (-6.55%)
KIN (Common Stock)
Previous Close Volume
$8.85 253,816
Intraday High Intraday Low
$8.84 $8.27
52 Week High 52 Week Low
$15.75 $8.05
Exchange: NASDAQ CM

KindredBio proudly supports
Rabies Free Africa

© Copyright 2012-2019 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. Suite 200 Burlingame, CA 94010 | Privacy Policy| Website Terms of Use| Forward Looking Statements
Scroll to top